Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders (CBD_ADD_IN) | C4C

This study involves the administration of Cannabidiol (CBD), a non-psychoactive molecule derived from the Cannabis plant, as and adjunctive therapy for people with psychosis who have shown a poor response to their standard treatment with antipsychotic and are still symptomatic. The study is an open-label, therapeutic exploratory trial. Participants (n=20) meeting entry-criteria will receive 6-weeks’ treatment with CBD (starting dose 400mg/d; thereafter flexible dosing 200-800mg/d). We will use brain imaging methods (MRI) before starting CBD and following 6 weeks of treatment to determine if there are any imaging biomarkers that predict response to CBD, to determine if CBD treatment has an effect on these markers, and whether there are any changes that correspond to improvement in symptoms following CBD treatment. We will also compare metabolic indices at baseline with those following the addition of CBD treatment.